Syros Pharmaceuticals, Inc. (SYRS)
SYRS Stock Price Chart
Explore Syros Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze SYRS price movements and trends.
SYRS Company Profile
Discover essential business fundamentals and corporate details for Syros Pharmaceuticals, Inc. (SYRS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Jun 2016
Employees
68.00
Website
https://www.syros.comCEO
James E. Bradner
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
SYRS Financial Timeline
Browse a chronological timeline of Syros Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Oct 2025
Earnings released on 4 Jun 2025
Earnings released on 20 May 2025
Earnings released on 26 Mar 2025
EPS came in at -$1.19 falling short of the estimated -$0.70 by -70.00%.
Earnings released on 31 Oct 2024
EPS came in at -$0.68 surpassing the estimated -$0.76 by +10.53%.
Earnings released on 31 Jul 2024
EPS came in at -$0.70 surpassing the estimated -$0.79 by +11.39%.
Earnings released on 14 May 2024
EPS came in at -$0.79 surpassing the estimated -$0.89 by +11.24%.
Earnings released on 27 Mar 2024
EPS came in at -$1.19 surpassing the estimated -$1.23 by +3.25%, while revenue for the quarter reached $386.00K , missing expectations by -80.70%.
Earnings released on 14 Nov 2023
EPS came in at -$1.35 falling short of the estimated -$1.12 by -20.54%, while revenue for the quarter reached $3.76M , beating expectations by +88.10%.
Earnings released on 8 Aug 2023
EPS came in at -$1.30 falling short of the estimated -$1.11 by -17.12%, while revenue for the quarter reached $2.83M , missing expectations by -19.06%.
Earnings released on 10 May 2023
EPS came in at -$0.85 surpassing the estimated -$1.12 by +24.11%, while revenue for the quarter reached $2.95M , missing expectations by -9.39%.
Earnings released on 2 Mar 2023
EPS came in at -$1.28 falling short of the estimated -$1.27 by -0.79%, while revenue for the quarter reached -$5.47M , missing expectations by -242.00%.
Earnings released on 14 Nov 2022
EPS came in at -$2.41 surpassing the estimated -$3.91 by +38.36%, while revenue for the quarter reached $3.89M , missing expectations by -24.88%.
Stock split effective on 19 Sept 2022
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Aug 2022
EPS came in at -$5.40 falling short of the estimated -$4.20 by -28.57%, while revenue for the quarter reached $6.28M , beating expectations by +32.41%.
Earnings released on 16 May 2022
EPS came in at -$4.00 surpassing the estimated -$4.80 by +16.67%, while revenue for the quarter reached $5.47M , beating expectations by +11.04%.
Earnings released on 15 Mar 2022
EPS came in at -$4.20 surpassing the estimated -$4.40 by +4.55%, while revenue for the quarter reached $7.80M , beating expectations by +62.30%.
Earnings released on 5 Nov 2021
EPS came in at -$4.10 surpassing the estimated -$4.30 by +4.65%, while revenue for the quarter reached $5.70M , beating expectations by +29.77%.
Earnings released on 5 Aug 2021
EPS came in at -$3.60 matching the estimated -$3.60, while revenue for the quarter reached $5.16M , beating expectations by +24.99%.
Earnings released on 6 May 2021
EPS came in at -$2.30 surpassing the estimated -$5.50 by +58.18%, while revenue for the quarter reached $4.83M , missing expectations by -25.93%.
Earnings released on 4 Mar 2021
EPS came in at -$6.10 falling short of the estimated -$5.40 by -12.96%, while revenue for the quarter reached $5.70M .
Earnings released on 5 Nov 2020
EPS came in at -$4.30 falling short of the estimated -$3.80 by -13.16%, while revenue for the quarter reached $3.83M , beating expectations by +13.16%.
SYRS Stock Performance
Access detailed SYRS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.